NEW STUDY. Immunotherapy is very effective for many cancers, but the treatment can also cause autoimmune adverse events. Encephalitis is one of the most serious and difficult-to-diagnose adverse events of immunotherapy. A simple blood test may detect treatment-triggered encephalitis at an early stage. This finding is reported in a study by researchers at the University of Gothenburg. The study also provides new clues on possible mechanism behind serious adverse events from immunotherapy.
Immunotherapy with checkpoint inhibitors has revolutionized cancer treatment. The treatment activates the patient’s own immune defense to attacks cancer cells. Checkpoint inhibitors activate the immune response by blocking signaling pathways that normally act as inhibitors of the patient’s T cells. With the treatment, many patients with widespread malignant melanoma, for example, can become tumor free, or even cured, but autoimmune adverse events are common and sometimes very serious.
Extreme immune activation
“It is now possible for patients with metastases in the brain to become completely tumor-free, which is fantastic. In some patients, however, the activation of the immune response becomes so extreme that also healthy tissue becomes severely inflamed,” says the study’s first author Sara Bjursten, who is a PhD student at Sahlgrenska Academy at the University of Gothenburg and a specialist in oncology at Sahlgrenska University Hospital.
The study was recently published in the Journal of ImmunoTherapy of Cancer and is the result of a collaboration between researchers in oncology, rheumatology and clinical neurochemistry in Gothenburg.
“We show that simple blood tests, several already established as routine tests, can likely be used to see early on which patients are developing severe encephalitis. This offers a better opportunity to adapt the treatment and to administer anti-inflammatory drugs in time.”
An early marker
The first part of the study is a case study showing that the brain damage marker S-100B in blood samples can act as an early warning for encephalitis during immunotherapy. The levels of S-100B in blood rose even before the encephalitis gave symptoms. At the peak of encephalitis symptoms, newer brain damage markers were analyzed, such as GFAP and NFL. Plasma levels of these markers were very high at this point and later decreased in parallel with clinical improvement.
The researchers believe that these simple blood tests can be key in diagnosing treatment-induced encephalitis, which today is difficult to diagnose because the symptoms can be misinterpreted as tumor growth, stroke or infection.
“In Gothenburg, we now use S-100B and NFL to monitor the risk of encephalitis and we hope to soon be able to include GFAP and Tau. The markers have helped us diagnose three more cases of treatment-triggered encephalitis,” says the study’s last author Max Levin, who is an associate professor at Sahlgrenska Academy at the University of Gothenburg and chief physician in oncology at Sahlgrenska University Hospital.
Free of tumors with immunotherapy
The patient case that sparked the researchers’ interest was a man who was treated at Sahlgrenska University Hospital a few years ago, where malignant melanoma had spread to the brain with metastases. His brain metastases shrank rapidly from the double checkpoint inhibition treatment he received, but he also developed such severe encephalitis that he became paralyzed and almost died. Examining his blood tests, the researchers noted the connection between the marker and the encephalitis.
After two years of rehabilitation, the patient was still tumor-free and had learned to walk shorter distances again.
Special T cells
Another exciting finding in the study shows that T cells in patients with serious adverse events differ from T cells in identically treated patients without adverse events. Compared to patients without side effects, patients with serious side effects had higher levels of the activating receptor ICOS on their T cells, which act as an accelerator. The highest T cell levels of ICOS were detected in the patient with encephalitis.
“It is an interesting finding. No specific property of T cells has previously been demonstrated in adverse reactions. The analyses we developed together with Professor Anna Rudin include a battery of activating and inhibitory T cell receptors. ICOS was the receptor that stood out strikingly in patients with serious adverse events. It is possible that pharmacological blocking of ICOS is an effective way to stop encephalitis and other life-threatening side effects,” according to Max Levin.
Could have important implications
Researchers continue to investigate whether a combination of brain injury markers can provide even better opportunities for detecting serious brain side effects early in immunotherapy. The research results may affect existing international guidelines for the clinical treatment connected to immunotherapy. According to published data, about one percent of those who receive immunotherapy suffer from the side effect of encephalitis, but the researchers have clinical data suggesting that figure may be higher.
Title: Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis; doi:10.1136/jitc-2021-002732
https://pubmed.ncbi.nlm.nih.gov/34215689/
